NASDAQ:REPL - Replimune Group Stock Price, Forecast & News

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group Inc (NASDAQ:REPL) posted its quarterly earnings results on Thursday, February, 13th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.10. View Replimune Group's Earnings History.

Replimune Group is scheduled to release their next quarterly earnings announcement on Friday, June 26th 2020. View Earnings Estimates for Replimune Group.

5 brokerages have issued 12 month price targets for Replimune Group's stock. Their forecasts range from $12.50 to $30.00. On average, they anticipate Replimune Group's share price to reach $24.10 in the next year. This suggests a possible upside of 43.0% from the stock's current price. View Analyst Price Targets for Replimune Group.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Replimune Group.

News stories about REPL stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Replimune Group earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Replimune Group.

Replimune Group saw a increase in short interest in January. As of January 31st, there was short interest totalling 578,100 shares, an increase of 6.4% from the January 15th total of 543,500 shares. Based on an average daily volume of 189,200 shares, the days-to-cover ratio is presently 3.1 days. Approximately 4.7% of the shares of the company are sold short. View Replimune Group's Current Options Chain.

Some companies that are related to Replimune Group include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS), Twist Bioscience (TWST), Adverum Biotechnologies (ADVM) and BAVARIAN NORDIC/S (BVNRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Fate Therapeutics (FATE), Myovant Sciences (MYOV), Amarin (AMRN), Energy Transfer LP Unit (ET), Pfizer (PFE), Axsome Therapeutics (AXSM), Cronos Group (CRON), Immunomedics (IMMU) and Sangamo Therapeutics (SGMO).

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Replimune Group's stock is owned by many different of retail and institutional investors. Top institutional investors include BVF Inc. IL (7.21%), FMR LLC (2.71%), Emerald Advisers LLC (2.48%), Emerald Mutual Fund Advisers Trust (2.46%), Victory Capital Management Inc. (1.03%) and Victory Capital Management Inc. (1.03%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, Joseph P Slattery, Philip Astley-Sparke and Robert Coffin. View Institutional Ownership Trends for Replimune Group.

REPL stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Goldman Sachs Group Inc. and New York State Common Retirement Fund. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Philip Astley-Sparke and Robert Coffin. View Insider Buying and Selling for Replimune Group.

REPL stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, FMR LLC, Marshall Wace North America L.P., Emerald Advisers LLC, Bank of Montreal Can, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC and Victory Capital Management Inc.. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes and Joseph P Slattery. View Insider Buying and Selling for Replimune Group.

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REPL stock can currently be purchased for approximately $16.85.

Replimune Group has a market capitalization of $617.55 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe.View Additional Information About Replimune Group.

The official website for Replimune Group is http://www.replimune.com/.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-995-2443 or via email at [email protected]